Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

内科学 cGMP特异性磷酸二酯酶5型
作者
Irwin Goldstein,Tom F. Lue,Harin Padma-Nathan,Raymond C. Rosen,William D. Steers,Pierre A. Wicker
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:338 (20): 1397-1404 被引量:1821
标识
DOI:10.1056/nejm199805143382001
摘要

BACKGROUND Sildenafil is a potent inhibitor of cyclic guanosine monophosphate hydrolysis [corrected] in the corpus cavernosum and therefore increases the penile response to sexual stimulation. We evaluated the efficacy and safety of sildenafil, administered as needed in two sequential double-blind studies of men with erectile dysfunction of organic, psychogenic, and mixed causes. METHODS In a 24-week dose-response study, 532 men were treated with oral sildenafil (25, 50, or 100 mg) or placebo. In a 12-week, flexible dose-escalation study, 329 different men were treated with sildenafil or placebo, with dose escalation to 100 mg based on efficacy and tolerance. After this dose-escalation study, 225 of the 329 men entered a 32-week, open-label extension study. We assessed efficacy according to the International Index of Erectile Function, a patient log, and a global-efficacy question. RESULTS In the dose-response study, increasing doses of sildenafil were associated with improved erectile function (P values for increases in scores for questions about achieving and maintaining erections were <0.001). For the men receiving 100 mg of sildenafil, the mean score for the question about achieving erections was 100 percent higher after treatment than at base line (4.0 vs. 2.0 of a possible score of 5). In the last four weeks of treatment in the dose-escalation study, 69 percent of all attempts at sexual intercourse were successful for the men receiving sildenafil, as compared with 22 percent for those receiving placebo (P<0.001). The mean numbers of successful attempts per month were 5.9 for the men receiving sildenafil and 1.5 for those receiving placebo (P<0.001). Headache, flushing, and dyspepsia were the most common adverse effects in the dose-escalation study, occurring in 6 percent to 18 percent of the men. Ninety-two percent of the men completed the 32-week extension study. CONCLUSIONS Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助科研通管家采纳,获得10
1秒前
搜集达人应助科研通管家采纳,获得10
1秒前
溫蒂应助科研通管家采纳,获得200
1秒前
赘婿应助科研通管家采纳,获得10
1秒前
丘比特应助科研通管家采纳,获得10
1秒前
Jasper应助科研通管家采纳,获得10
1秒前
共享精神应助科研通管家采纳,获得10
1秒前
Ava应助科研通管家采纳,获得10
1秒前
Liens发布了新的文献求助10
1秒前
无花果应助科研通管家采纳,获得10
1秒前
Lucas应助科研通管家采纳,获得10
1秒前
乐乐应助科研通管家采纳,获得10
1秒前
桐桐应助科研通管家采纳,获得10
1秒前
科目三应助科研通管家采纳,获得10
1秒前
CodeCraft应助科研通管家采纳,获得10
1秒前
在水一方应助科研通管家采纳,获得10
2秒前
2秒前
无风发布了新的文献求助10
2秒前
safett应助科研通管家采纳,获得10
2秒前
量子星尘发布了新的文献求助10
2秒前
千寻发布了新的文献求助10
2秒前
2秒前
独特的兰发布了新的文献求助10
2秒前
摆烂发布了新的文献求助10
3秒前
XXU完成签到,获得积分10
3秒前
3秒前
3秒前
茯苓完成签到,获得积分10
3秒前
烟花应助wendy采纳,获得10
4秒前
return33完成签到,获得积分10
4秒前
4秒前
CodeCraft应助Kyle采纳,获得30
5秒前
6秒前
6秒前
冷艳的二娘完成签到,获得积分10
6秒前
7秒前
lyx完成签到,获得积分20
7秒前
8秒前
金鱼咕噜噜luu完成签到,获得积分10
8秒前
华仔应助高家琚采纳,获得10
8秒前
高分求助中
(禁止应助)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Plutonium Handbook 4000
International Code of Nomenclature for algae, fungi, and plants (Madrid Code) (Regnum Vegetabile) 1500
Functional High Entropy Alloys and Compounds 1000
Building Quantum Computers 1000
Molecular Cloning: A Laboratory Manual (Fourth Edition) 500
Social Epistemology: The Niches for Knowledge and Ignorance 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4232807
求助须知:如何正确求助?哪些是违规求助? 3766187
关于积分的说明 11833112
捐赠科研通 3424730
什么是DOI,文献DOI怎么找? 1879435
邀请新用户注册赠送积分活动 932290
科研通“疑难数据库(出版商)”最低求助积分说明 839512